Attovia expands its IPO filing to 17M shares at an estimated $17, but retail access is still unverified (2026)

August 4, 2026 is a regular NYSE trading day. The date is not on the exchange's 2026 holiday or early-close list. 1

Today's spotlight: Attovia Therapeutics (ATTO)

Status: Attovia's latest SEC registration filing, submitted August 4, is still preliminary. It shows 17 million shares at an estimated $17 per share, with estimated net proceeds of $265.1 million. That implies about $289 million in gross proceeds before fees if the estimate holds. 2

That is a meaningful change from the July 29 filing, which showed 12.5 million shares at $15 to $17 and estimated net proceeds of $182.4 million. IPOScoop's public calendar still shows those older terms and an expected August 5 Nasdaq debut, so the final price and share count are not locked yet. 3 4

Business in one sentence: Attovia is a clinical-stage biotech developing multi-target biologic drugs for immune-mediated diseases through its ATTOBODY platform. Its lead program, ATTO-1310, is in Phase 1 for severe itching and related skin disease; ATTO-2306 and ATTO-1091 are earlier programs. 5 6

Why retail investors care: this is a large financing for a company that is still proving its first clinical programs. The latest filing reports about $115.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, before the IPO. Attovia expects to start a Phase 2 trial for ATTO-1310 by the first half of 2027. The offering would give the company more capital to reach that milestone, but it does not reduce the clinical risk. 2

Risk to monitor: Attovia has no products approved for commercial sale and has not generated product revenue. ATTO-1310 remains a Phase 1 program. A delayed or unsuccessful move into Phase 2 by the stated first-half-2027 target would be a clear reason to reassess the pipeline story. 2

Minimum buy-in and broker access: No public US retail allocation was verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. That leaves the minimum buy-in unconfirmed. An ATTO listing on a brokerage app would mean ordinary secondary-market trading, not proof that the IPO was available at the offer price.

Actionable now

No US IPO allocation met all four checks for this brief: public terms, a live deadline, a minimum buy-in, and a verified path through a mainstream retail broker. Calendar entries confirm upcoming deals, but they are not retail order notices. 4 7

Ticker	Price range	Minimum buy-in	Deadline	Verified brokers	Status
None verified	-	-	No public US allocation window found	None publicly verified	Watch only

ATTO, BRVE, and VOGX remain listing-watch names until a public allocation notice supplies the missing access and deadline details.

Market pulse

The near-term calendar is biotech-heavy. Renaissance lists six current-week US deals: five biotech or therapeutics offerings and one bank IPO. The listed biotech sizes add up to about $972 million, led by Braveheart Bio at $300 million and Latigo at $272 million. That is a concentration of proposed supply, not proof of investor demand. 7
Two SPAC units are marked priced today. IPOScoop lists ARC Group Securities Acquisition I at $10 per unit and BOA Acquisition Corp. II at $10 per unit, with estimated deal sizes of $105 million and $125 million. These are pricing or trading events, not verified public allocations for ordinary brokerage customers. 4
The demand signal is missing. The accessible Attovia filing and public calendars do not provide an oversubscription multiple or a mainstream-broker allocation confirmation. The larger share count in the new filing shows a larger proposed financing; it does not tell you how strong the order book is. 2

HK desk

NASN TECH (2261) is closed for new applications in this edition. ET Net lists an offer range of HK$10.42 to HK$11.18 for a 100-share board lot, so the face-value minimum was HK$1,042 to HK$1,118 before fees. The application period ended at noon Hong Kong time on August 4, and the expected listing date is August 7. 8

NASN TECH develops intelligent-driving motion-control technology, with a focus on brake-by-wire systems. ET Net's August 4 new-listings memorandum confirms the August 7 debut. It does not identify a second active public offer in the same memo, so there is no additional verified Hong Kong action item here. 9

On the radar: August 5-12

The public profiles below give expected listing dates but do not separately disclose pricing dates. No pricing night is inferred.

Deal	Pricing date	Expected listing	Terms	Why watch
Braveheart Bio (BRVE)	Not disclosed	Aug. 6	18.8M shares at $15-$17; est. $300M	Clinical-stage HCM drug candidate headed for planned global Phase 3 trials. 10
Vogenx (VOGX)	Not disclosed	Aug. 6	6.25M shares at $11-$13; est. $75M	Phase 2B metabolic program for post-bariatric hypoglycemia; the company has never generated revenue. 11
BlossomHill Therapeutics (BLSM)	Not disclosed	Aug. 7	7.81M shares at $15-$17; est. $125M	Phase 1/2 lung-cancer program with an FDA end-of-Phase 1 meeting planned for Q4 2026. 12
Latigo Biotherapeutics (LTGO)	Not disclosed	Aug. 7	16M shares at $16-$18; est. $272M	Phase 3-ready, non-opioid oral therapies for acute and chronic pain. 13
Londian Wason New Energy Tech (FOIL)	Not disclosed	Aug. 12	3.57M ADS at $20-$22; est. $75M	Makes copper foil used in lithium-ion batteries, giving the calendar a non-biotech industrial name. 14